Home  /  Resource Library  /  Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Results of a study examining the combinations of rituximab and bendmustine as well as cytarabine and rituximab followed by autologous stem cell transplant for treament of MCL.